Author(s)

Yuanlong Zhou ¹, Jisen Zhao ¹, Yuan Wang ¹, Hao Lu ¹

Affiliation(s)

¹ Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, China

Corresponding Author

Hao Lu

ABSTRACT

This paper aims to investigate the synergistic effects of PD-1 inhibitors combined with CTLA-4 inhibitors in HCC immunotherapy. Eighty liver cancer patients admitted to our hospital from January 2022 to September 2024 were selected and divided into control group and observation group according to the random number table method, with 40 cases in each group. The observation group received PD-1 suppression. Preparation was monotherapy and the control group received PD-1 inhibitor combined with CTLA-4 inhibitor. Overall survival (OS) was observed. Progression-free survival. The degree of tumor reduction. And adverse reactions. After treatment, the observation group was better than the control group in terms of overall survival, progression-free survival and tumor shrinkage, and the overall incidence of adverse reactions in the observation group was lower than that in the control group. This study provides a clinical basis for the combination of PD-1 inhibitors and CTLA-4 inhibitors in the immunotherapy of HCC.

KEYWORDS

PD-1 inhibitor; CTLA-4 inhibitor; cancer of the liver; Immunotherapy; synergistic effects

CITE THIS PAPER

Yuanlong Zhou, Jisen Zhao, Yuan Wang, Hao Lu, Analysis of synergistic effects of PD-1 inhibitors and CTLA-4 inhibitors in HCC immunotherapy. MEDS Basic Medicine (2024) Vol. 2: 136-139. DOI: http://dx.doi.org/10.23977/medbm.2024.020219.

REFERENCES

[1] Zhao Gangjun, Wu Yuanbo et al, Progress in combined immunotherapy based on PD-1 / PD-L1 in cancer[J].The chemistry of life, 2020, 40(12):2236-2242.
[2] Liu Kang, Zhong Xiaojuan, Yuan Huozhong et al, Progress in PD-1 / PD-L1 inhibitor combination therapy in cancer immunotherapy [J]. Modern oncology medicine, 2019, 27(24):4487-4494.
[3] Yu Xiaojuan, Yu Chuanfei, Liu Chunyu et al, Quality evaluation of the bispecific antibodies against PD-1 / CTLA-4[J]. The Chinese Journal of Biological Products, 2023, 36(10):1198-1205.
[4] Liming Liao, Huilin Xu et al, Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies[J].Frontiers of Medicine, 2023, 17(5):805-822. 

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine